by Rod Raynovich | Sep 20, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Continuing from Part 1 here are some specific comments on interesting companies. Adeona Pharmaceuticals (AEN) Amex ($0.83) Market Cap $19M, $25M Sh. Outstanding Adeona is a development stage drug Company focused in CNS that in -licenses clinical stage product...
by Rod Raynovich | Sep 16, 2010 | 2024-25 Life Science Portfolios, BIOgraph
We attended the R&R Conference in NYC this week and here is a brief summary: Over 5000 people were registered with hundreds of companies presenting in healthcare, metals and mining,energy and China. Chinese companies were a significant presence for the first time...
by Rod Raynovich | Sep 8, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Zymogenetics (ZGEN) stock soared 84% today on the $9.75 ($885M)buyout offer from Bristol-Myers Squibb (BMY). Bristol was also up 1% even though the acquisition is dilutive to 2011 earnings. Bristol was seeking the the ZGEN Hepatitis C drug PEG-Interferon lamda which...
by Rod Raynovich | Sep 1, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Biotech stocks perked up today emboldened by a new month and ISM data including some positive growth from China’s manufacturing sector. Apple headlines with the iPOD and Apple TV helped catalyze the NASDAQ move. Biotech went along for the ride with most...
by Rod Raynovich | Aug 26, 2010 | 2024-25 Life Science Portfolios, Macro
Sequel to our Aug 11 post on “End of Summer Rally” If you hedged or exited stock positions on August 11 or a couple of days earlier you would have saved 5% and much more on tech and smaller cap stocks.Since John Chambers of Cisco came on with his...
by Rod Raynovich | Aug 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The IPO market is setting up for continued investor interest in the biotech sector. Two high profile genomics companies,Complete Genomics and Pacific Biosciences, have filed S-1 Registration Statements with plans to go public in the fourth quarter around the time when...
by Rod Raynovich | Aug 12, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Microfluidics released earnings on Tuesday with good results: $4.5M in Q2 Revenue a 30% increase over the same quarter in 2009. Net Income of $143k compared to a loss of $177k in the same quarter of 2009.($396k before EBITA). Achieved a gross margin of 64%. Began...
by Rod Raynovich | Aug 3, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Q1 P Original Price % Return Q 2 P 8/2/10 % Recom 3/29/10 P Ret. Abaxis ABAX 26.8 2/2/09 15 79 21.2 20.7 30 Celera CRA 6.8 3/28/10 7 6.49 6.85 -2 Exact Sci EXAS UR 4.2 Genomic Health GHDX UR 12.6 13.1 Genoptix GXDX UR 17.2 18.13 GenProbe GPRO 48 2/2/09 45 7 46.3 45.9...
by Rod Raynovich | Jul 30, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The intersection of good earnings and a strong AACC showing boosted Diagnostic stocks this week with the following big movers today on earnings reports: Abaxis (ABAX) $20.81 up $13.7%,GenProbe (GPRO) $45.85 up 8.14%,Neogen (NEOG) $29.85 up 3.4% and Quidel (QDEL)...
by Rod Raynovich | Jul 29, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports. Rayno Diagnostic and Tools Portfolio Abaxis (ABAX)-under review- and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading...
